(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean Abraham|Nature Communications|2025Cited by 13
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Steven Kupczak et al.|Cancer Research|2024Cited by 7
Data from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Unknown|2025Cited by 1
Figure 4 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Unknown|2025Cited by 0